THE CHEMICAL INDUSTRY IN ITALY: SITUATION AND OUTLOOK

December 25, 2018

In the years following the crisis, the Italian industry has changed profoundly and has strengthened its competitiveness, increasingly orienting itself towards international markets. In particular, it has repositioned towards medium-high technology sectors (mechanics, pharmaceuticals, the chemical industry itself) and, even in the so-called traditional sectors, it has strengthened innovative contents, as evidenced by the sharp increase in patent applications.

Spotlight

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious cardiometabolic lipid disorders. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disor

OTHER WHITEPAPERS
news image

How to Improve Furnace Efficiency With Pulse Firing

whitePaper | March 23, 2023

Improving productivity while reducing fuel consumption and emissions are high priorities for industrial furnace, oven and dryer manufacturers. Because such equipment often heats in-process materials to very high temperatures

Read More
news image

Solutions for Ammonia Gas Detection: A Comparison Summary

whitePaper | October 21, 2022

The hazardous, toxic, and combustible nature of ammonia is wellknown in industrial settings. Undetected ammonia leaks in production

Read More
news image

AMMONIUM NITRATE EXPLOSIONS

whitePaper | June 20, 2022

The catastrophic explosion in Beirut was one of the worst accidents caused by ammonium nitrate (AN) in history. Since the explosion, there has been a dramatic increase in interest concerning the safety aspects of AN.

Read More
news image

A META-ANALYSIS OF ROAD TRANSPORT EMISSIONS MODELS

whitePaper | May 22, 2022

The authors thank Pramoda Gode, Joshua Miller of ICCT, Puneet Kamboj of CEEW, Gerald Ollivier of the World Bank, and Pierpaolo Cazzola and Craglia Matteo, both of ITF, for helpful reviews. Any errors are the authors’ own.

Read More
news image

The Oil & Gas Drone Data Playbook

whitePaper | May 28, 2021

As an oil & gas professional, you encounter some of the most challenging and complex work and regulatory environments of any industry. Tasked with scouting new potential sites, you also oversee current construction; manage large fields, hundreds of oil rigs, and dozens of contractors; and secure miles of pipeline – all while keeping workers, the general public, and surrounding environments safe. Meanwhile, complicated and ever-evolving regulations make it difficult for oil & gas companies to streamline work.

Read More
news image

Planet Positive Chemicals

whitePaper | September 24, 2022

Climate action in the global chemical industry is lagging compared to other sectors. As of August 2022, only seventeen industry players had committed to targets in line with a 1.5 degrees future as part of the Science Based Targets initiative (SBTi).

Read More

Spotlight

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious cardiometabolic lipid disorders. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disor

Events